MOVANTIK

This brand name is authorized in Canada, New Zealand, United States

Active ingredients

The drug MOVANTIK contains one active pharmaceutical ingredient (API):

1 Naloxegol UNII 65I14TNM33 - NALOXEGOL OXALATE

Naloxegol is a PEGylated derivative of the mu-opioid receptor antagonist naloxone. PEGylation reduces naloxegol’s passive permeability and also renders the compound a substrate for the P-glycoprotein transporter. Naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in the gastrointestinal tract, thereby decreasing the constipating effects of opioids without impacting opioid-mediated analgesic effects on the central nervous system. Read about Naloxegol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MOVANTIK Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A06AH03		A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AH Peripheral opioid receptor antagonists
Discover more medicines within A06AH03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02442167, 02442175
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 18231, 18232
Country: US	FDA, National Drug Code	Identifier(s): 0310-1969, 0310-1970, 55700-383, 57841-1300, 57841-1301